相似文献
1
Measure for measure: minimal residual disease in CLL.
Blood. 2016 Dec 15;128(24):2747-2748. doi: 10.1182/blood-2016-11-745323.
2
[Analysis of immunophenotype characteristics in 109 cases of B lineage chronic B lymphoid leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Dec;19(6):1374-7.
3
Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Lab Med. 2016 May;47(2):103-11. doi: 10.1093/labmed/lmw006.
4
CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.
Leukemia. 1999 Oct;13(10):1501-5. doi: 10.1038/sj.leu.2401511.
5
Definition and diagnosis of sporadic and familial chronic lymphocytic leukemia.
Hematol Oncol Clin North Am. 2004 Aug;18(4):783-94, vii. doi: 10.1016/j.hoc.2004.04.009.
6
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7.
7
Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Leukemia. 2002 Aug;16(8):1460-9. doi: 10.1038/sj.leu.2402584.
8
The detection of minimal residual disease status in chronic lymphocytic leukemia.
Cytometry B Clin Cytom. 2011 Nov;80(6):344-5. doi: 10.1002/cyto.b.20625.
9
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Br J Haematol. 2014 Aug;166(3):360-8. doi: 10.1111/bjh.12887. Epub 2014 Apr 16.
10
Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Int J Lab Hematol. 2014 Apr;36(2):165-71. doi: 10.1111/ijlh.12149. Epub 2013 Sep 13.
引用本文的文献
1
Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia.
JNCI Cancer Spectr. 2018 Dec 19;2(4):pky069. doi: 10.1093/jncics/pky069. eCollection 2018 Oct.
本文引用的文献
1
The 21st century revolution in CLL: Why this matters to patients.
Best Pract Res Clin Haematol. 2016 Mar;29(1):122-132. doi: 10.1016/j.beha.2016.08.008. Epub 2016 Aug 11.
2
Minimal residual disease is an independent predictor for 10-year survival in CLL.
Blood. 2016 Dec 15;128(24):2770-2773. doi: 10.1182/blood-2016-05-714162. Epub 2016 Oct 3.
3
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
J Clin Oncol. 2016 Nov 1;34(31):3758-3765. doi: 10.1200/JCO.2016.67.1305.
4
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
Blood. 2016 Jan 21;127(3):279-86. doi: 10.1182/blood-2015-08-634816. Epub 2015 Nov 17.
5
Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
Ann Oncol. 2016 Jan;27(1):10-5. doi: 10.1093/annonc/mdv507. Epub 2015 Oct 21.
6
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Blood. 2014 Mar 20;123(12):1810-7. doi: 10.1182/blood-2013-09-527853. Epub 2014 Jan 10.
7
The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?
Hematol Oncol Clin North Am. 2013 Apr;27(2):267-88. doi: 10.1016/j.hoc.2013.01.005.
8
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
J Clin Oncol. 2012 Mar 20;30(9):980-8. doi: 10.1200/JCO.2011.36.9348. Epub 2012 Feb 13.
9
Biomarkers and surrogate end points--the challenge of statistical validation.
Nat Rev Clin Oncol. 2010 Jun;7(6):309-17. doi: 10.1038/nrclinonc.2010.43. Epub 2010 Apr 6.
10
Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.
Blood. 2006 Jun 1;107(11):4563-9. doi: 10.1182/blood-2005-09-3634. Epub 2006 Jan 31.
Zotero 插件